Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib

@inproceedings{Guo2016HeightenedBC,
  title={Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib},
  author={Ailin Guo and Pin Lu and Natalie Galanina and Chadi Nabhan and Sonali M Smith and Morton Coleman and Y. Lynn Wang},
  booktitle={Oncotarget},
  year={2016}
}
In chronic lymphocytic leukemia (CLL), patients with unmutated immunoglobulin heavy chain variable region gene (UM-CLL) have worse outcomes than mutated CLL (M-CLL) following chemotherapy or chemoimmunotherapy. However, in the era of BCR-targeted therapies, the adverse prognostic impact of unmutated IGHV seems to be diminishing, and there are clinical datasets showing unexpected improved responses in UM-CLL. We investigated the biological differences of BTK activity between these subgroups and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.

Expert opinion on pharmacotherapy • 2017
View 13 Excerpts
Highly Influenced

Drug-perturbation-based stratification of blood cancer

The Journal of clinical investigation • 2018

Small Molecules in Hematology

Recent Results in Cancer Research • 2018

Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2017
View 1 Excerpt

Chronic lymphocytic leukaemia

Nature Reviews Disease Primers • 2017

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.

British journal of haematology • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…